Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-06

AUTHORS

Brett P. Monia, Joseph F. Johnston, Thomas Geiger, Marcel Muller, Doriano Fabbro

ABSTRACT

Substantial evidence exists supporting a direct role for raf kinases in the development and maintenance of certain human malignancies. Here we test the potential of phosphorothioate antisense oligodeoxynucleotides targeted against human C–raf–1 kinase to specifically inhibit C–raf–1 kinase gene expression and tumor progression in cell culture and in vivo, using human tumor xenograft mouse models. Treatment of human tumor cells with appropriate phosphorothioate antisense oligodeoxynucleotides led to specific inhibition of C–raf kinase gene expression in cell culture and in vivo at well–tolerated doses. Moreover, oligodeoxynucleotide treatment resulted in potent antiproliferative effects in cell culture and potent antitumor effects in vivo against a variety of tumor types that were highly consistent with an antisense mechanism of action for these compounds. These studies strongly suggest that antisense inhibitors targeted against C–raf–1 kinase may be of considerable value as antineoplastic agents that display activity against a wide spectrum of tumor types at well–tolerated doses. More... »

PAGES

668-675

Journal

TITLE

Nature Medicine

ISSUE

6

VOLUME

2

Related Patents

  • Raf Kinase Modulator Compounds And Methods Of Use Thereof
  • Raf Kinase Modulator Compounds And Methods Of Use Thereof
  • Cyclic Substituted Fused Pyrrolocarbazoles And Isoindolones
  • Using Polyamide Nucleic Acid Oligomers To Engender A Biological Response
  • For Treatment Of Endocrine-Regulated Tumors, For Example, Breast, Prostate, Ovarian And Colon Cancers
  • Treatment Of Cancer By Inhibition Of Igfbps And Clusterin
  • The Serine/Threonine Kinase Family Includes Members That Regulate Cell Growth, Migration, Differentiation, Gene Expression, Muscle Contraction, Glucose Metabolism, Cellular Protein Synthesis, And Regulation Of The Cell Cycle
  • {1-Methyl-5-[2-(5-Trifluoromethyl-1h-Imidazol-2-Yl)-Pyridin-4-Yloxy]-1h-Benzoimidazol-2-Yl}-(4-Trifluoromethyl-Phenyl)-Amine; Inhibitors Of Kinase/ Raf Kinase Activity Associated With Tumorigenesis, Serine/Threonine Kinase Or Receptor Tyrosine Kinase; Cancer; Tumors; Inhibitmapk Signaling Pathway
  • Chimeric Oligonucleotide Comprising Phosphorothioate Internucleotide Linkage And Complementary To Gene Is Orally Administered
  • {1-Methyl-5-[2-(5-Trifluoromethyl-1h-Imidazol-2-Yl)-Pyridin-4-Yloxy]-1h-Benzoimidazol-2-Yl}-(4-Trifluoromethyl-Phenyl)-Amine; Inhibitors Of Kinase/Raf Kinase Activity Associated With Tumorigenesis, Serine/Threonine Kinase Or Receptor Tyrosine Kinase; Cancer; Tumors; Inhibit Mapk Signaling Pathway
  • Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
  • Compounds, Processes And Intermediates For Synthesis Of Mixed Backbone Oligomeric Compounds
  • Using Polyamide Nucleic Acid Oligomers To Engender A Biological Response
  • Ink4c-P18 And Ink4d-P19, Inhibitors Of Cyclin-Dependent Kinases Cdk4 And Cdk6, And Uses Thereof
  • Synthesizing Oligonucleotide By Deblocking And Coupling Nucleotides Together, Then Treating With Oxidizing Solution To Convert H-Phosphonate Linkages To Phosphodiester, Phosphorothioate, Phosphoramidate Or Boranophosphate
  • Methods Of Modulating Serine/Threonine Protein Kinase Function With Azabenzimidazole-Based Compounds
  • Antibodies To Retinoid Metabolizing Protein
  • Bispecific Antisense Oligonucleotides That Inhibit Igfbp-2 And Igfbp-5 And Methods Of Using Same
  • Bispecific Oligonucleotide For The Treatment Of Cns Malignancies
  • Substituted Benzimidazoles And Methods Of Their Use
  • Nucleotide Sequence That Codes For A Protein That Oxides A Retinoid; For The Treatment Of Cancer; Anticarcinogenic Agents
  • Compositions And Methods For The Modulation Of The Expression Of B7 Protein
  • Orally Administering A Chimeric Oligonucleotide That Has Alkylphosphonate , Phosphorodithioate, Alkylphosphonothioate, Phosphoramidite, Phosphate Ester, Carbamate, Carbonate, Phosphate Triester, Acetamidate, And Carboxymethyl Ester Linkages
  • Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
  • Ω-Carboxyl Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
  • Methods Of Modulating Serine/Thereonine Protein Kinase Function With Quinazoline-Based Compounds
  • Method For Achieving Desired Glial Growth Factor 2 Plasma Levels
  • Antisense Nucleic Acids
  • Modified Protein Kinase A-Specific Oligonucleotides And Methods Of Their Use
  • Antisense Nucleic Acids
  • Retinoid Metabolizing Protein
  • Method For Achieving Desired Glial Growth Factor 2 Plasma Levels
  • Anticarcinogenic/Antitumor/Antiproliferative Agents And Diagnostic Agents Targeted Against Gene Which Codes For A Protein Kinase Involved In Signal Transduction
  • Comprises Nucleotide Sequences Coding Tumor Marker Protein For Treating And Diagnosing Cancer; Gene Expression Inhibition; Antisense Therapy; Antitumor Agents
  • Method For Identifying Accessible Binding Sites On Rna
  • Aryl Ureas With Angiogenisis Inhibiting Activity
  • Jak/Stat Inhibitors And Mapk/Erk Inhibitors For Rsv Infection
  • Methods Of Modulating Serine/Threonine Protein Kinase Function With Quinazoline-Based Compounds
  • Kinase Inhibitor; Alzheimer's Disease; Central Nervous System Disorders; Antiinflamamtory Agents; Skin Disorders; Osteoporosis; Atherosclerosis; Restenosis; Thrombosis; Antidiabetic Agents; Viricides; Fungicides
  • Carbamides Such As N-(3-Tert-Butylphenyl)-N'-(4-(3-(N-Methyl-Carbamoyl)Phenoxy)Phenyl Urea, Used As Enzyme Inhibitors And As Anticarcinogenic Agents
  • Bispecific Oligonucleotide For The Treatment Of Cns Malignancies
  • Hybrid Oligonucleotides And Uses Thereof
  • Modulating Apoptosis Or Proliferation Of A Cancer Cell, Comprising Regulating Expression Of Shinc-2
  • Aryl Urea Compounds In Combination With Other Cytostatic Or Cytotoxic Agents For Treating Human Cancers
  • Antisense Nucleic Acids
  • Kiaa0175 Inhibitor Is Selected From The Group Consisting Of An Anti-Sense Molecule, A Ribozyme, An Antibody, An Antibody Fragment, A Protein, A Polypeptide And A Small Molecule.
  • Antisense Oligonucleotide Modulation Of Raf Gene Expression
  • Methods Of Using Aryl Ureas To Treat Diseases Mediated By The Vegf Induced Signal Transduction Pathway Characterized By Abnormal Angiogenesis Or Hyperpermeability Processes.
  • 2-Indolinone Derivatives As Multi-Target Protein Kinase Inhibitors And Histone Deacetylase Inhibitors
  • Treatment Of Cancer By Inhibition Of Igfbps And Clusterin
  • Antisense Nucleic Acids
  • 3-({4-[1-(2,2-Difluoroethyl)-3-(1h-Pyrrolo[2,3-B]Pyridin-5-Yl)-1h-Pyrazol-4-Yl]Pyrimidin-2-Yl}Amino)Propanenitrile, Used As Serine/Threonine Protein Kinase Inhibitors, For The Treatment Of Disease States Associated With Abnormal Cell Growth Such As Cancer
  • Retinoid Metabolizing Protein
  • An Oligonucleotide That Encodes A Human Protein Kinases Involved In Signal Transduction Regulating Cell Proliferation; Anticarcinogenic/Antitumor Agents, Diagnosis And Therapy Of Psoriasis, Artherosclerosis, Tissue Grafts
  • Antisense Nucleic Acids
  • Methods Of Modulating Serine/Threonine Protein Kinase Function With Azabenzimidazole-Based Compounds
  • Method For Achieving Desired Glial Growth Factor 2 Plasma Levels
  • Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors And Histone Deacetylase Inhibitors
  • Antisense Nucleic Acids
  • Hybridization And Rnace Activation In A Cell With Oligonucleotides
  • Antisense Oligonucleotide Modulation Of Raf Gene Expression
  • Oligoribonucleotides And Ribonucleases For Cleaving Rna
  • Method Of Down-Regulating Gene Expression
  • Chimeric Antisense Oligonucleotides Of Arabinofuranose Analogue And Deoxyribose Nucleotides
  • Method For Identifying Accessible Binding Sites On Rna
  • Bispecific Antisense Oligonucleotides That Inhibit Igfbp-2 And Igfbp-5 And Methods Of Using Same
  • Aryl Ureas With Angiogenesis Inhibiting Activity
  • Oligonucleotides Which Contain Region(S) Of 2'-Modified Nucleosides Connected By Alternating Phosphodiester And Phosphorothioate Linkages; Use As Antisense Agents, Assaying A Nucleic Acid; Nuclease Resistant
  • Modulate Nucleic Acid Activation
  • Preventing And Treating Serine/Threonine Protein Kinase-Related Abnormal Conditions In Mammals Associated With An Aberration In A Signal Transduction Pathway Such As Cancer Or A Fibrotic Disorder
  • Oligonucleotide Compositions And Methods For The Modulation Of The Expression Of B7 Protein
  • Diaryl Ureas For Diseases Mediated By Pdgfr
  • Treatment Of Cancer By Inhibition Of Igfbps And Clusterin
  • Treatment Of Cancer By Inhibition Of Igfbp's And Clusterin
  • Methods For The Treatment Of Cancer
  • For Therapy Of Autoimmune Disease, Inflammatory Disease, For Inhibiting Allograft Rejection
  • Treatment Of Cancer By Inhibition Of Igfbps And Clusterin
  • Agents For The Regulation Of Protein Kinase
  • Retinoid Metabolizing Protein
  • Modified Protein Kinase A-Specific Oligonucleotides And Methods Of Their Use
  • Pyridine, Quinoline, And Isoquinoline N-Oxides As Kinase Inhibitors
  • Substituted Pyrimidine Derivatives Useful In The Treatment Of Cancer And Other Disorders
  • Bispecific Antisense Oligonucleotides That Inhibit Igfbp-2 And Igfbp-5 And Methods Of Using Same
  • Such As {1-Methyl-5-[2-(5-Trifluoromethyl-1h-Imidazol-2-Yl)-Pyridin-4-Yloxy]-1h-Benzoimidazol-2-Yl}-(4-Trifluoromethyl-Phenyl)-Amine Via Reduction, Desulfurization; For Treating Kinase Mediated Disorders
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nm0696-668

    DOI

    http://dx.doi.org/10.1038/nm0696-668

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1039646445

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/8640558


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Base Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Division", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gene Expression Regulation, Neoplastic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lung Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice, Inbred BALB C", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Molecular Sequence Data", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasms, Experimental", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oligodeoxyribonucleotides, Antisense", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oligonucleotides, Antisense", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Serine-Threonine Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins c-raf", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "RNA, Messenger", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Thionucleotides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transplantation, Heterologous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Cells, Cultured", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Molecular Pharmacology, Isis Pharmaceuticals, 2280 Faraday Avenue, 92008, Carlsbad, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.282569.2", 
              "name": [
                "Department of Molecular Pharmacology, Isis Pharmaceuticals, 2280 Faraday Avenue, 92008, Carlsbad, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Monia", 
            "givenName": "Brett P.", 
            "id": "sg:person.01344750652.90", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344750652.90"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Molecular Pharmacology, Isis Pharmaceuticals, 2280 Faraday Avenue, 92008, Carlsbad, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.282569.2", 
              "name": [
                "Department of Molecular Pharmacology, Isis Pharmaceuticals, 2280 Faraday Avenue, 92008, Carlsbad, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Johnston", 
            "givenName": "Joseph F.", 
            "id": "sg:person.01016273314.94", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016273314.94"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology, Ciba-Geigy Limited, CH-4002, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419481.1", 
              "name": [
                "Department of Oncology, Ciba-Geigy Limited, CH-4002, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Geiger", 
            "givenName": "Thomas", 
            "id": "sg:person.0676041204.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676041204.53"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology, Ciba-Geigy Limited, CH-4002, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419481.1", 
              "name": [
                "Department of Oncology, Ciba-Geigy Limited, CH-4002, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Muller", 
            "givenName": "Marcel", 
            "id": "sg:person.012524430742.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012524430742.96"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology, Ciba-Geigy Limited, CH-4002, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419481.1", 
              "name": [
                "Department of Oncology, Ciba-Geigy Limited, CH-4002, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fabbro", 
            "givenName": "Doriano", 
            "id": "sg:person.01342570171.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342570171.22"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nm0695-541", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012035936", 
              "https://doi.org/10.1038/nm0695-541"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1195-1116", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022849626", 
              "https://doi.org/10.1038/nm1195-1116"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1195-1119", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052115793", 
              "https://doi.org/10.1038/nm1195-1119"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/364352a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051824867", 
              "https://doi.org/10.1038/364352a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/364308a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021693984", 
              "https://doi.org/10.1038/364308a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-642-72624-8_97", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024254887", 
              "https://doi.org/10.1007/978-3-642-72624-8_97"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1996-06", 
        "datePublishedReg": "1996-06-01", 
        "description": "Substantial evidence exists supporting a direct role for raf kinases in the development and maintenance of certain human malignancies. Here we test the potential of phosphorothioate antisense oligodeoxynucleotides targeted against human C\u2013raf\u20131 kinase to specifically inhibit C\u2013raf\u20131 kinase gene expression and tumor progression in cell culture and in vivo, using human tumor xenograft mouse models. Treatment of human tumor cells with appropriate phosphorothioate antisense oligodeoxynucleotides led to specific inhibition of C\u2013raf kinase gene expression in cell culture and in vivo at well\u2013tolerated doses. Moreover, oligodeoxynucleotide treatment resulted in potent antiproliferative effects in cell culture and potent antitumor effects in vivo against a variety of tumor types that were highly consistent with an antisense mechanism of action for these compounds. These studies strongly suggest that antisense inhibitors targeted against C\u2013raf\u20131 kinase may be of considerable value as antineoplastic agents that display activity against a wide spectrum of tumor types at well\u2013tolerated doses.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nm0696-668", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1113716", 
            "issn": [
              "1078-8956", 
              "1546-170X"
            ], 
            "name": "Nature Medicine", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "2"
          }
        ], 
        "keywords": [
          "phosphorothioate antisense oligodeoxynucleotides", 
          "tumor types", 
          "antisense oligodeoxynucleotides", 
          "human tumor xenograft mouse model", 
          "tumor xenograft mouse model", 
          "potent antitumor effects", 
          "xenograft mouse model", 
          "potent antiproliferative effects", 
          "cell cultures", 
          "certain human malignancies", 
          "kinase gene expression", 
          "human tumor cells", 
          "mouse model", 
          "antitumor effects", 
          "c-Raf", 
          "tumor progression", 
          "antineoplastic agents", 
          "human malignancies", 
          "antiproliferative effects", 
          "tumor cells", 
          "oligodeoxynucleotide treatment", 
          "gene expression", 
          "antitumor activity", 
          "specific inhibition", 
          "antisense inhibitor", 
          "substantial evidence", 
          "doses", 
          "vivo", 
          "c-Raf kinase", 
          "treatment", 
          "direct role", 
          "wide spectrum", 
          "oligodeoxynucleotides", 
          "kinase", 
          "Raf kinase", 
          "malignancy", 
          "expression", 
          "progression", 
          "antisense mechanism", 
          "inhibitors", 
          "activity", 
          "inhibition", 
          "culture", 
          "effect", 
          "cells", 
          "considerable value", 
          "agents", 
          "evidence", 
          "study", 
          "role", 
          "action", 
          "human c-raf", 
          "types", 
          "maintenance", 
          "mechanism", 
          "development", 
          "potential", 
          "variety", 
          "compounds", 
          "values", 
          "model", 
          "spectra"
        ], 
        "name": "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase", 
        "pagination": "668-675", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1039646445"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nm0696-668"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "8640558"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nm0696-668", 
          "https://app.dimensions.ai/details/publication/pub.1039646445"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:21", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_286.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nm0696-668"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nm0696-668'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nm0696-668'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nm0696-668'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nm0696-668'


     

    This table displays all metadata directly associated to this object as RDF triples.

    266 TRIPLES      21 PREDICATES      116 URIs      102 LITERALS      29 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nm0696-668 schema:about N06b924a4eab2473c99bd17ef9ef67884
    2 N0a99fd41ccb34abc94034f68b406c022
    3 N128736bf71f2416381642cb818933e7a
    4 N17374a9a60c14dbfba39ad87efeea31b
    5 N20297f54e3dd4fe484267c774f05de39
    6 N2fec617b14ed41b6be209393babeb242
    7 N360306b013a94743b06515e821bd227a
    8 N3622215b2d0a47ef9439ef8039bee3b9
    9 N4cf3e9b13d064ddc9241ef11548093bc
    10 N7985fa60ff0f42bb8f2bca6d5ce88bb7
    11 N80cdcd8949a34e219a8ce05ab0a44a64
    12 N8503c10cc6ee409292ac776489599214
    13 N90f2789f36a74252985ed6ca5d0c2bcb
    14 N94e658161e9d46d2b39f695bb9f9dfaa
    15 Na3253c9444db49c29c95d4bea87fa23c
    16 Na52448c6e2f74d75a804f1f8a0570fdd
    17 Nb287f5c5b4724c0581b9d30e4670903e
    18 Nba972f7b6adb4fa6ad207bd1429bd7a3
    19 Nccd1346d36694652bc941a8a0b5d4b01
    20 Nd25a53df53d44d19a1e07ef3cfdfd245
    21 Ndcc9d7f4ba8f4ee6b78816620217fba4
    22 Ndef598949b5c46979924c5d3d7b1a075
    23 anzsrc-for:11
    24 anzsrc-for:1112
    25 schema:author Nd8669b9910b441ee85f3feb928070509
    26 schema:citation sg:pub.10.1007/978-3-642-72624-8_97
    27 sg:pub.10.1038/364308a0
    28 sg:pub.10.1038/364352a0
    29 sg:pub.10.1038/nm0695-541
    30 sg:pub.10.1038/nm1195-1116
    31 sg:pub.10.1038/nm1195-1119
    32 schema:datePublished 1996-06
    33 schema:datePublishedReg 1996-06-01
    34 schema:description Substantial evidence exists supporting a direct role for raf kinases in the development and maintenance of certain human malignancies. Here we test the potential of phosphorothioate antisense oligodeoxynucleotides targeted against human C–raf–1 kinase to specifically inhibit C–raf–1 kinase gene expression and tumor progression in cell culture and in vivo, using human tumor xenograft mouse models. Treatment of human tumor cells with appropriate phosphorothioate antisense oligodeoxynucleotides led to specific inhibition of C–raf kinase gene expression in cell culture and in vivo at well–tolerated doses. Moreover, oligodeoxynucleotide treatment resulted in potent antiproliferative effects in cell culture and potent antitumor effects in vivo against a variety of tumor types that were highly consistent with an antisense mechanism of action for these compounds. These studies strongly suggest that antisense inhibitors targeted against C–raf–1 kinase may be of considerable value as antineoplastic agents that display activity against a wide spectrum of tumor types at well–tolerated doses.
    35 schema:genre article
    36 schema:isAccessibleForFree false
    37 schema:isPartOf N22fc85710a724ee685d44ebf47d2733b
    38 Ndff7d0a1f47c4d689f5b780040183a02
    39 sg:journal.1113716
    40 schema:keywords Raf kinase
    41 action
    42 activity
    43 agents
    44 antineoplastic agents
    45 antiproliferative effects
    46 antisense inhibitor
    47 antisense mechanism
    48 antisense oligodeoxynucleotides
    49 antitumor activity
    50 antitumor effects
    51 c-Raf
    52 c-Raf kinase
    53 cell cultures
    54 cells
    55 certain human malignancies
    56 compounds
    57 considerable value
    58 culture
    59 development
    60 direct role
    61 doses
    62 effect
    63 evidence
    64 expression
    65 gene expression
    66 human c-raf
    67 human malignancies
    68 human tumor cells
    69 human tumor xenograft mouse model
    70 inhibition
    71 inhibitors
    72 kinase
    73 kinase gene expression
    74 maintenance
    75 malignancy
    76 mechanism
    77 model
    78 mouse model
    79 oligodeoxynucleotide treatment
    80 oligodeoxynucleotides
    81 phosphorothioate antisense oligodeoxynucleotides
    82 potent antiproliferative effects
    83 potent antitumor effects
    84 potential
    85 progression
    86 role
    87 specific inhibition
    88 spectra
    89 study
    90 substantial evidence
    91 treatment
    92 tumor cells
    93 tumor progression
    94 tumor types
    95 tumor xenograft mouse model
    96 types
    97 values
    98 variety
    99 vivo
    100 wide spectrum
    101 xenograft mouse model
    102 schema:name Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
    103 schema:pagination 668-675
    104 schema:productId N059b2283060043bfbcf09cdb3d774201
    105 N1d246877a711426f86b7b5d1eb90cee7
    106 N2ae428d84486491eb38010411ffb73d3
    107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039646445
    108 https://doi.org/10.1038/nm0696-668
    109 schema:sdDatePublished 2022-12-01T06:21
    110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    111 schema:sdPublisher N56e80137d8da4f199fd8cbb7b37160ab
    112 schema:url https://doi.org/10.1038/nm0696-668
    113 sgo:license sg:explorer/license/
    114 sgo:sdDataset articles
    115 rdf:type schema:ScholarlyArticle
    116 N04799937abe841d6a7b4a099f3a40d27 rdf:first sg:person.0676041204.53
    117 rdf:rest N56c4518a2144423f8717655f622bbb9f
    118 N059b2283060043bfbcf09cdb3d774201 schema:name dimensions_id
    119 schema:value pub.1039646445
    120 rdf:type schema:PropertyValue
    121 N06b924a4eab2473c99bd17ef9ef67884 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name Humans
    123 rdf:type schema:DefinedTerm
    124 N0a99fd41ccb34abc94034f68b406c022 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Oligonucleotides, Antisense
    126 rdf:type schema:DefinedTerm
    127 N128736bf71f2416381642cb818933e7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Base Sequence
    129 rdf:type schema:DefinedTerm
    130 N17374a9a60c14dbfba39ad87efeea31b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Lung Neoplasms
    132 rdf:type schema:DefinedTerm
    133 N1d246877a711426f86b7b5d1eb90cee7 schema:name pubmed_id
    134 schema:value 8640558
    135 rdf:type schema:PropertyValue
    136 N20297f54e3dd4fe484267c774f05de39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Mice
    138 rdf:type schema:DefinedTerm
    139 N22fc85710a724ee685d44ebf47d2733b schema:issueNumber 6
    140 rdf:type schema:PublicationIssue
    141 N2ae428d84486491eb38010411ffb73d3 schema:name doi
    142 schema:value 10.1038/nm0696-668
    143 rdf:type schema:PropertyValue
    144 N2fec617b14ed41b6be209393babeb242 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Molecular Sequence Data
    146 rdf:type schema:DefinedTerm
    147 N360306b013a94743b06515e821bd227a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name RNA, Messenger
    149 rdf:type schema:DefinedTerm
    150 N3622215b2d0a47ef9439ef8039bee3b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Cell Division
    152 rdf:type schema:DefinedTerm
    153 N4cf3e9b13d064ddc9241ef11548093bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Animals
    155 rdf:type schema:DefinedTerm
    156 N56c4518a2144423f8717655f622bbb9f rdf:first sg:person.012524430742.96
    157 rdf:rest N9ef1d5fb187546db80f112f66ca9a00f
    158 N56e80137d8da4f199fd8cbb7b37160ab schema:name Springer Nature - SN SciGraph project
    159 rdf:type schema:Organization
    160 N7985fa60ff0f42bb8f2bca6d5ce88bb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Dose-Response Relationship, Drug
    162 rdf:type schema:DefinedTerm
    163 N80cdcd8949a34e219a8ce05ab0a44a64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Protein Serine-Threonine Kinases
    165 rdf:type schema:DefinedTerm
    166 N8503c10cc6ee409292ac776489599214 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Proto-Oncogene Proteins c-raf
    168 rdf:type schema:DefinedTerm
    169 N90f2789f36a74252985ed6ca5d0c2bcb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Neoplasms, Experimental
    171 rdf:type schema:DefinedTerm
    172 N94e658161e9d46d2b39f695bb9f9dfaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Gene Expression Regulation, Neoplastic
    174 rdf:type schema:DefinedTerm
    175 N9ef1d5fb187546db80f112f66ca9a00f rdf:first sg:person.01342570171.22
    176 rdf:rest rdf:nil
    177 Na0e2fac8986946d491ef379436fc2071 rdf:first sg:person.01016273314.94
    178 rdf:rest N04799937abe841d6a7b4a099f3a40d27
    179 Na3253c9444db49c29c95d4bea87fa23c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    180 schema:name Thionucleotides
    181 rdf:type schema:DefinedTerm
    182 Na52448c6e2f74d75a804f1f8a0570fdd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    183 schema:name Antineoplastic Agents
    184 rdf:type schema:DefinedTerm
    185 Nb287f5c5b4724c0581b9d30e4670903e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    186 schema:name Tumor Cells, Cultured
    187 rdf:type schema:DefinedTerm
    188 Nba972f7b6adb4fa6ad207bd1429bd7a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Proto-Oncogene Proteins
    190 rdf:type schema:DefinedTerm
    191 Nccd1346d36694652bc941a8a0b5d4b01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Transplantation, Heterologous
    193 rdf:type schema:DefinedTerm
    194 Nd25a53df53d44d19a1e07ef3cfdfd245 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Mice, Inbred BALB C
    196 rdf:type schema:DefinedTerm
    197 Nd8669b9910b441ee85f3feb928070509 rdf:first sg:person.01344750652.90
    198 rdf:rest Na0e2fac8986946d491ef379436fc2071
    199 Ndcc9d7f4ba8f4ee6b78816620217fba4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    200 schema:name Carcinoma
    201 rdf:type schema:DefinedTerm
    202 Ndef598949b5c46979924c5d3d7b1a075 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Oligodeoxyribonucleotides, Antisense
    204 rdf:type schema:DefinedTerm
    205 Ndff7d0a1f47c4d689f5b780040183a02 schema:volumeNumber 2
    206 rdf:type schema:PublicationVolume
    207 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    208 schema:name Medical and Health Sciences
    209 rdf:type schema:DefinedTerm
    210 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    211 schema:name Oncology and Carcinogenesis
    212 rdf:type schema:DefinedTerm
    213 sg:journal.1113716 schema:issn 1078-8956
    214 1546-170X
    215 schema:name Nature Medicine
    216 schema:publisher Springer Nature
    217 rdf:type schema:Periodical
    218 sg:person.01016273314.94 schema:affiliation grid-institutes:grid.282569.2
    219 schema:familyName Johnston
    220 schema:givenName Joseph F.
    221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016273314.94
    222 rdf:type schema:Person
    223 sg:person.012524430742.96 schema:affiliation grid-institutes:grid.419481.1
    224 schema:familyName Muller
    225 schema:givenName Marcel
    226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012524430742.96
    227 rdf:type schema:Person
    228 sg:person.01342570171.22 schema:affiliation grid-institutes:grid.419481.1
    229 schema:familyName Fabbro
    230 schema:givenName Doriano
    231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342570171.22
    232 rdf:type schema:Person
    233 sg:person.01344750652.90 schema:affiliation grid-institutes:grid.282569.2
    234 schema:familyName Monia
    235 schema:givenName Brett P.
    236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344750652.90
    237 rdf:type schema:Person
    238 sg:person.0676041204.53 schema:affiliation grid-institutes:grid.419481.1
    239 schema:familyName Geiger
    240 schema:givenName Thomas
    241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676041204.53
    242 rdf:type schema:Person
    243 sg:pub.10.1007/978-3-642-72624-8_97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024254887
    244 https://doi.org/10.1007/978-3-642-72624-8_97
    245 rdf:type schema:CreativeWork
    246 sg:pub.10.1038/364308a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021693984
    247 https://doi.org/10.1038/364308a0
    248 rdf:type schema:CreativeWork
    249 sg:pub.10.1038/364352a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051824867
    250 https://doi.org/10.1038/364352a0
    251 rdf:type schema:CreativeWork
    252 sg:pub.10.1038/nm0695-541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012035936
    253 https://doi.org/10.1038/nm0695-541
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1038/nm1195-1116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022849626
    256 https://doi.org/10.1038/nm1195-1116
    257 rdf:type schema:CreativeWork
    258 sg:pub.10.1038/nm1195-1119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052115793
    259 https://doi.org/10.1038/nm1195-1119
    260 rdf:type schema:CreativeWork
    261 grid-institutes:grid.282569.2 schema:alternateName Department of Molecular Pharmacology, Isis Pharmaceuticals, 2280 Faraday Avenue, 92008, Carlsbad, California, USA
    262 schema:name Department of Molecular Pharmacology, Isis Pharmaceuticals, 2280 Faraday Avenue, 92008, Carlsbad, California, USA
    263 rdf:type schema:Organization
    264 grid-institutes:grid.419481.1 schema:alternateName Department of Oncology, Ciba-Geigy Limited, CH-4002, Basel, Switzerland
    265 schema:name Department of Oncology, Ciba-Geigy Limited, CH-4002, Basel, Switzerland
    266 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...